Payment overview · 2025
General Payments
$12,960.00
50 reported records · 12 companies
Healthcare provider profile · identity verified
Henry Norman Small, M.D.
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · HOUSTON, TX · NPI 1720022320
Verified facts
What the public records show
CMS Open Payments records show Henry Norman Small, M.D. received $12,960.00 in general payments during 2025 across 50 reported records.
Osseus Fusion Systems, LLC accounted for 76.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tymlos.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Osseus Fusion Systems, LLC | Unresolved — no canonical attribution shown | $9,858.38 | 76.1% | 1 | 2025 |
| Intrinsic Therapeutics | Unresolved — no canonical attribution shown | $2,212.54 | 17.1% | 14 | 2025 |
| Alafair Biosciences, Inc. | Unresolved — no canonical attribution shown | $281.58 | 2.2% | 6 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $179.29 | 1.4% | 17 | 2025 |
| Xtant Medical Inc | Unresolved — no canonical attribution shown | $137.36 | 1.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$63.34 | 0.5% | 2 | 2025 |
| Life Spine, Inc. | Unresolved — no canonical attribution shown | $62.32 | 0.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $58.73 | 0.5% | 2 | 2025 |
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.67 | 0.3% | 2 | 2025 |
| EBI, LLC | Unresolved — no canonical attribution shown | $29.49 | 0.2% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $19.40 | 0.1% | 1 | 2025 |
| Providence Medical Technology, Inc. | Unresolved — no canonical attribution shown | $13.90 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $9,858.38 | 1 |
| Food and Beverage | $1,834.51 | 47 |
| Travel and Lodging | $1,267.11 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BARRICAID ACD (ANNULAR CLOSURE DEVICE) Normalized: barricaid acd annular closure device |
Device | Intrinsic Therapeutics | $2,212.54 | 14 | 2025 |
Source payment records
|
|||||
| VersaWrap Normalized: versawrap |
Device | Alafair Biosciences, Inc. | $281.58 | 6 | 2025 |
Source payment records
|
|||||
| AVATAR MINIMALLY INVASIVE SPINAL SYSTEM Normalized: avatar minimally invasive spinal system |
Device | Life Spine, Inc. | $62.32 | 1 | 2025 |
Source payment records
|
|||||
| Dyna-Link Ti Normalized: dyna link ti |
Device | Life Spine, Inc. | $62.32 | 1 | 2025 |
Source payment records
|
|||||
| ProLift Normalized: prolift |
Device | Life Spine, Inc. | $62.32 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $58.73 | 2 | 2025 |
Source payment records
|
|||||
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| PLASMABLADE(TM) Normalized: plasmablade tm |
Device | Medtronic, Inc. | $36.55 | 1 | 2025 |
Source payment records
|
|||||
| BIOMET SPINALPAK NON-INVASIVE SPINE FUSION STIMULATOR SYSTEM Normalized: biomet spinalpak non invasive spine fusion stimulator system |
Device | EBI, LLC | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| Biomet OrthoPak Non-invasive Bone Growth Stimulator System Normalized: biomet orthopak non invasive bone growth stimulator system |
Device | EBI, LLC | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| EBI OSTEOGEN IMPLANTABLE BONE GROWTH STIMULATOR Normalized: ebi osteogen implantable bone growth stimulator |
Device | EBI, LLC | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| SPF XL IIB IMPLANTABLE SPINAL FUSION STIMULATOR Normalized: spf xl iib implantable spinal fusion stimulator |
Device | EBI, LLC | $29.49 | 1 | 2025 |
Source payment records
|
|||||
| AQUAMANTYS(TM) Normalized: aquamantys tm |
Device | Medtronic, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Tymlos tymlos |
2025 | Tymlos | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 36 |
| Gabapentin | Gabapentin | 73 | 13 |
| Celecoxib | Celecoxib | 64 | 12 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Belbuca | Buprenorphine Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,960.00 · 50 records | Osseus Fusion Systems, LLC | AQUAMANTYS(TM), AVATAR MINIMALLY INVASIVE SPINAL SYSTEM, BARRICAID ACD (ANNULAR CLOSURE DEVICE), BIOMET SPINALPAK NON-INVASIVE SPINE FUSION STIMULATOR SYSTEM, Biomet OrthoPak Non-invasive Bone Growth Stimulator System, Dyna-Link Ti, EBI OSTEOGEN IMPLANTABLE BONE GROWTH STIMULATOR, HEMOBLAST BELLOWS, PLASMABLADE(TM), ProLift, SPF XL IIB IMPLANTABLE SPINAL FUSION STIMULATOR, Tymlos, VersaWrap, ZYNRELEF | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tymlos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Radius Health, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error